Compare Colgate-Palmolive Company (CL) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs Charles River Laboratories Intl. Inc — how do they compare? Colgate-Palmolive Company trades at $92.59 (market cap $73.59B), while Charles River Laboratories Intl. Inc trades at $287.81 (market cap $13.46B). The key difference: Colgate-Palmolive Company is far larger — about 5.5× Charles River Laboratories Intl. Inc's market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CL | CRL | |
|---|---|---|
Market Cap | $73.59B | $13.46B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $282.00 |
52-Week Low | $74.98 | $145.57 |
Enterprise Value | $80.07B | $16.30B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $92.66, down 0.53% on the day, with a neutral technical signal. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% sales growth driven by strength in Latin America and Asia Pacific, though North American performance remains weak. Operating cash flow remains robust at $4.20 billion for 2025. The stock is trading below the consensus price target of $99.10.
The outlook is mixed, with strong profitability and consistent earnings beats offset by high valuation multiples and domestic market challenges. The primary opportunity lies in international growth and margin expansion, while risks include intense competition and reliance on emerging markets for growth.
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
